Grace Therapeutics Inc. Ordinary Shares GRCE 深 沪
等待开盘 08-14 09:30:00 美东时间
3.28
+0.075
+2.34%
华盛通- 最 高3.40
- 今 开3.19
- 成交量 13.23万股
- 最 低 3.1498
- 昨 收 3.205
- 总市值 3325.89万
- 52周最高 4.965
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 1.75
- 委 比 -90.36%
- 总股本 1013.99万
- 历史最高 2016.00
- 量 比 1.49
- 振 幅 7.81%
- 历史最低 1.75
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Grace Therapeutics Q1 EPS $(0.21) Beats $(0.22) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4.55 percent.
08-12 20:07
Grace Therapeutics Submits NDA To FDA For GTx-104; Submission Seeks Approval Of GTx-104 In Treatment Of Patients With Aneurysmal Subarachnoid Hemorrhage
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of
06-25 20:02
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Grace Therapeutics submitted its New Drug Application (NDA) to the FDA for GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The application includes positive results from the Phase 3 STRIVE-ON safety trial, which showed GTx-104 met its primary endpoint with a 19% reduction in clinically significant hypotension compared to oral nimodipine. The submission could trigger up to $7.6 million in warra...
06-25 12:00
Grace Therapeutics Reports Promising Drug Development Progress
Acasti Pharma, Inc. ( ($GRCE) ) has released its Q4 earnings. Here is a breakdo...
06-24 11:52
Grace Therapeutics GAAP EPS of -$0.79
Grace Therapeutics press release (NASDAQ:GRCE): FY GAAP EPS of -$0.79. At March 31, 2025, the Company had cash and cash equivalents of $22.1 million, a net decrease of $0.9 million compared to cash an...
06-23 20:17
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Grace Therapeutics held a Type C meeting with the FDA regarding their planned NDA submission for GTx-104, which is on track for submission by mid-2025. The company reported successful completion of the STRIVE-ON trial, meeting its primary endpoint and showing potential clinical benefits compared to oral nimodipine. They secured $15 million in private placement financing, with potential for an additional $15 million, strengthening their cash posit...
06-23 12:00
Grace Therapeutics to Participate in the 2025 BIO International Conference
Grace Therapeutics Inc. announced that CEO Prashant Kohli will attend the BIO 2025 International Conference in Boston. The event, hosted by BIO, is the largest biotechnology gathering globally, connecting leaders in life sciences. Kohli will be available for meetings via BIO’s partnering platform or email. The company focuses on developing GTx-104, an IV formulation of nimodipine for treating aSAH, a rare and severe type of stroke. GTx-104 uses n...
06-13 12:00
美股大行评级 | 潜在涨幅348%！万达生物制药获机构升目标价至20美元，维持“买入”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1098890886600560640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Stoke Therapeutics(STOK)"买入"评级，目标价从35美元升至47美元</p> <p>• HC Wainwright & Co.：维持万达生物
02-19 10:24
Grace Therapeutics shares are trading higher after the company announced its Phase 3 STRIVE-ON safety trial of GTx-104 in aSAH met its primary endpoint. Additionally, the company announced a $30 million private placement.
Grace Therapeutics shares are trading higher after the company announced its Ph...
02-10 23:31
Grace therapeutics announces private placement financing of $30 million
Grace Therapeutics (NASDAQ:GRCE), formerly Acasti Pharma, on Monday said it has signed securities purchase agreements with new and existing healthcare focused institutional investors to raise up to ap...
02-10 21:15
